It is widely accepted that intake of dietary fats and chronic inflammation are risk factors for developing colorectal cancer. Arachidonic acid is a major component of animal fats, and the bioactive lipids produced from this substrate play critical roles in a variety of biologic processes, including cancer. Cyclooxygenase-derived prostaglandin E 2 is a known proinflammatory lipid mediator that promotes tumor progression. Metabolism of arachidonic acid by the cyclooxygenase pathway provides one mechanism for the contribution of dietary fats and chronic inflammation to carcinogenesis. In this review, we highlight recent advances in our understanding of how a proinflammatory mediator prostaglandin E 2 promotes colorectal cancer immune evasion. These findings may provide a rationale for the development of new therapeutic approaches to subvert tumor-induced immunosuppression.
C olorectal cancer (CRC) is the third or fourth most common malignant neoplasm and the second leading cause of cancer deaths in the United States, when including both sexes. Currently, the most effective treatment for CRC, including various approaches using surgical resection, radiation, and/or chemotherapy, works best when the disease is detected at a very early stage. Although colonoscopy screening is an effective way to detect and prevent CRC by removing precancerous adenomas, even today more than 50% of patients continue to present to their physician with advanced cancer for which standard treatments are not as effective, resulting in low 5-year survival rates. Thus, we have always known that a more effective approach to control cancer is to develop improved prevention and early detection measures. Chemoprevention and cancer vaccines have been considered plausible approaches for cancer prevention. A significant effort has been made in the development of novel drugs for both cancer prevention and treatment over the past 2 decades. One group of compounds found to have beneficial effects on reducing the risk of developing some solid tumors including the 4 most prevalent cancers worldwide (colorectal, breast, lung, and prostate cancer) is nonsteroidal anti-inflammatory drugs (NSAIDs), which primarily target the cyclooxygenase enzymes (COX-1 and COX-2). Epidemiologic and clinical studies have demonstrated that long-term use of NSAIDs reduces the relative risk of CRC by 40% to 50%. 1 Unlike COX-2 selective inhibitors (COXIBs) and other nonselective NSAIDs, long-term aspirin use is beneficial for prevention of both CRC and cardiovascular diseases. Treatment of familial adenomatous polyposis (FAP 2 ) patients with celecoxib significantly reduced the polyp burden, 2 whereas daily use of aspirin significantly suppressed polyp growth in FAP patients 3 and substantially reduced cancer incidence in patients with Lynch syndrome. 4 In sporadic CRC, 4 randomized controlled trials demonstrated that aspirin use reduced risk of adenoma recurrence in patients with a history of colorectal adenomas. 5Y8 More intriguingly, recent observational and clinical studies revealed that daily use of aspirin was associated with a reduced risk of metastatic spread 9 and inhibited the spread of primary tumor cells to other organs after the diagnosis of localized disease, in particular CRC, 10 suggesting the potential therapeutic efficacy of NSAIDs in advanced CRC. Furthermore, epidemiologic studies showed that regular use of aspirin specifically reduced risk of the subgroup of patients with high COX-2 levels. 11 Use of aspirin after the diagnosis of CRC at stages I, II, and III resulted in prolonged overall survival, especially among individuals whose tumors overexpressed COX-2. 12 These results suggest that the preventive and inhibitory effects of aspirin on CRC might depend on the presence of COX-2. Cyclooxygenase 2 expression is elevated in approximately 50% of colorectal adenomas and 85% of adenocarcinomas 13Y15 and is associated with a worse survival of CRC patients. 16 Cyclooxygenase enzymes catalyze the conversion of arachidonic acid into prostanoids, including prostaglandins (PGs) and thromboxane A 2 . These bioactive lipids exert their biological effects in an autocrine and/or paracrine manner by binding to their cognate cell surface G protein-coupled receptors ( Fig. 1 ). It has been hypothesized that some of the adverse cardiovascular effects related to NSAID use are associated with a global reduction in prostanoid production. 17 If this hypothesis is correct, one possible way to avoid these undesired effects is to target only COX-derived prostanoids that mediate the tumor-promoting effects. Among prostanoids, proinflammatory prostaglandin E 2 (PGE 2 ) plays a significant role in promoting tumor growth in CRC. Prostaglandin E 2 is the most abundant PG found in various types of human malignancies including colon, lung, breast, and head and neck cancer and is often associated with a poor prognosis. 18Y21 A urinary PGE 2 metabolite has been evaluated as a biomarker for CRC 22, 23 and for other cancer patients. 24Y27 The steady-state accumulation of PGE 2 in tumor tissues depends on the relative rates of COX-2/PGE synthaseYdependent biosynthesis and 15-hydroxyprostaglandin dehydrogenase (15-PGDH)Ydependent degradation ( Fig. 1 ). 15-Hydroxyprostaglandin dehydrogenase is highly expressed in normal tissues but is ubiquitously lost in many human cancers including CRC, 28, 29 lung, 30 and transitional bladder cancer. 31 Loss of 15-PGDH in these tumor tissues results in increased endogenous PGE 2 levels. More importantly, epidemiologic studies revealed that levels of urinary PGE 2 metabolite in healthy humans 32 and breast cancer patients 25, 26 are suppressed significantly not only by treatment with nonselective NSAIDs, including aspirin, but also by COXIBs, suggesting that the majority of PGE 2 formed in vivo may be derived from COX-2.
Direct evidence that PGE 2 promotes tumor growth came from our previous work and other studies showing that PGE 2 treatment dramatically increased both small and large intestinal adenoma burden in Apc Min/+ mice and significantly enhanced azoxymethane (AOM)-induced colon tumor incidence and multiplicity. 33, 34 Furthermore, elevated endogenous PGE 2 by genetic deletion of 15-Pgdh promotes colon tumor growth in Apc Min/+ and AOM mouse models. 35 In contrast, inhibition of endogenous PGE 2 by genetic deletion of PGE 2 synthase (mPges-1) suppresses intestinal tumor formation and growth in Apc Min/+ and AOM models. 36 The central role of PGE 2 in colorectal tumorigenesis has been further confirmed by evaluating mice with a homozygous deletion of individual PGE 2 receptors. 37Y39 Prostaglandin E 2 has been shown to promote tumor formation, growth, and metastasis by (1) directly inducing tumor epithelial cell proliferation, survival, and migration/invasion as well as epigenetic changes and (2) switching the tumor microenvironment from ''normal'' to one supporting tumor growth and metastatic spread by inhibiting immunosurveillance and inducing angiogenesis. 40, 41 Given that PGE 2 appears to play a dominant role in carcinogenesis, more selective pharmacological inhibition of PGE 2 production and signaling may be efficacious and may avoid some of the cardiovascular adverse effects associated with NSAIDs and COXIBs.
The roles of PGE 2 in colon tumor epithelial cells and tumor-associated angiogenesis have been summarized in recent reviews. 40, 42 In this review, we highlight recent breakthroughs in our understanding of the role of PGE 2 in tumor-induced immunosuppression.
PGE 2 AND IMMUNE CELLS
Colorectal cancer formation and progression depend on the escape from the host immunosurveillance. Crosstalk between transformed epithelial cells and their surrounding stromal cells switches a normal tissue microenvironment to one that supports tumor growth and spread by inducing angiogenesis and/or immune evasion. Similar to other solid tumors, CRC immune evasion involves a shift from T H 1 to T H 2 immune responses, a defective antigen-presenting cell (APC) function, impaired cytotoxic activity of CD8 + T cells and natural killer (NK) cell activity, and enhancement of immunosuppressive cells such as regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSCs). Emerging evidence supports the concept that PGE 2 signaling is one of the critical pathways that govern tumormediated immune dysfunction. Overall, PGE 2 contributes to a shift in the tumor microenvironment from anti-tumor responses to immunosuppressive responses ( Fig. 2 ). FIGURE 2. Models of proinflammatory PGE 2 in switching tumor microenvironment from anti-tumor to immunosuppressive responses. Following the initiation of epithelial tumors, the reciprocal interactions between transformed epithelial and immune cells play a key role in facilitating cancer progression. Proinflammatory PGE 2 produced by tumor epithelial cells and infiltrating immune cells is a key mediator in this crosstalk and can accelerate tumor growth and metastasis through evading attack by the immune system. Arachidonic acid (AA) is a polyunsaturated fatty acid that constitutes the phospholipid domain of most cell membranes and is liberated from the cellular membranes by cytoplasmic phospholipase A 2 (cPLA2). Free AA can be metabolized to eicosanoids through 3 major pathways: the COX, the lipoxygenase (LOX), and the cytochrome P450 monooxygenase pathway. In the COX pathway, the key step is the enzymatic conversion of the AA to intermediate PGG 2 , which is then reduced to an intermediate PGH 2 by the peroxidase activity of COX. Prostaglandin H 2 is sequentially metabolized to prostanoids, including PGs and thromboxanes (TXs) via specific PG and TX synthases. The MRP gene family is composed of efflux transporters for PGs, whereas PGT is an influx transporter for PGs. 15-Hydroxyprostaglandin mainly metabolizes the intracellular PGE 2 and PGF 2> to a stable 13,14-dihydro-15-keto-PGA 2 (PGEM) and 13,14-dihydro-15-keto-PGF 2> .
Antigen-Presenting Cells
Antigen-presenting cells include dendritic cells (DCs), monocytes/macrophages, and B cells.
Dendritic Cells
Dendritic cells, including myeloid DCs and plasmacytoid DCs, are thought to participate in tumor immunity by inducing primary and secondary T cell responses as well as immune tolerance. 43 Reduced DC numbers and activity are a prognostic indicator of patients with CRC. 44, 45 Mature DCs interact with antigen-specific T cells that initiate a T H 1-type immune response. For example, mature DCs pulsed with tumor cell lysate can induce tumor-specific cytotoxic T cell activity that inhibits colon tumor growth both in vitro and in mice implanted subcutaneously with CT26 colon tumor cells. 46 Immature DCs exhibit reduced phagocytic ability and reduced antigen presentation to T cells 47 and promote tumor angiogenesis by secreting proangiogenic cytokines. 48 In breast cancer patients, PGE 2 levels are positively correlated with inhibition of DC maturation. 47 Prostaglandin E 2 modulates the activities of DCs by altering their differentiation, maturation, and their ability to secrete cytokines ( Fig. 3) . Prostaglandin E 2 has been shown to induce intestinal immune tolerance via DCs in vivo. 49 In tumor implantation models of colon and lung cancers, PGE 2 promoted tumor growth by suppressing differentiation of DCs from bone marrow (BM) progenitors. 50 A recent study revealed that PGE 2 inhibited DC differentiation via down-regulation of retinal dehydrogenases (RALDH) in vitro and in vivo. 51 RALDH is the enzyme responsible for synthesis of retinoic acid that is required to modulate intestinal DC function. Another study reported that PGE 2 inhibited LPS-induced DC maturation via blocking LPS-induced indoleamine 2,3dioxygenase, interleukin 12 (IL-12) p70, and tumor necrosis factor > (TNF->) expression as well as the mature markers such as CD80, CD86, and major histocompatibility complex (MHC) class I in murine BM-derived DCs (BM-DCs). 52 Multiple in vitro studies elucidated the mechanisms underlying PGE 2 inhibition of DC function. Prostaglandin E 2 switches the function of DCs from induction of immunity to T cell tolerance via up-regulation of CD25 and indoleamine 2,3-dioxygenase. 53 Prostaglandin E 2 inhibits the antigen presentation ability of BM-DCs by up-regulation of IL-10. 54 Furthermore, PGE 2 shifts the IL-12/IL-23 balance in DCs via EP2 and EP4 receptors in favor of IL-23, which in turn increases the number of T H 17 cells in vitro. 55 Interleukin 12 promotes T H 1 responses and suppresses T H 17 development and function, whereas IL-23 is essential for T H 17 expansion and survival. Similarly, PGE 2 inhibits secretion of interferon > (IFN->) by Toll-like receptorYactivated plasmacytoid DCs via EP2/4, which results in reduction of T H 1 cytokine secretion and induction of T H 2 cytokine secretion by T cells. 56 Prostaglandin E 2 also inhibits the ability of DCs to produce CCL19 that attracts CCR7expressing naive CD4 + T cells. 57 More interestingly, PGE 2 was recently shown to redirect the differentiation of human DCs into monocytic MDSCs. 58 This body of work strongly supports the notion that PGE 2 represents a crucial signaling pathway regulating DC differentiation, maturation, and function.
states, depending on stimuli within the tumor/tissue microenvironment. The M1 designation is given for classically activated macrophages characterized by elevated expression of IL-12, TNF->, IL-23, and MHC class II. Also, M1 macrophages typically generate reactive nitrogen (NO) and oxygen intermediates (ROI) to counteract pathogens and tumor cells. In contrast, the M2 designation is for alternatively activated macrophages expressing high levels of IL-10, IL-4, and IL-13. In most cancers, tumor-associated macrophages (TAMs) resemble an M2-like phenotype 59 and are a major component of the leukocytic tumor infiltrate. The presence of TAMs is recognized as a poor prognostic sign in various tumors, including CRC. 60, 61 It has be well established that TAMs promote cancer progression and metastasis through supporting tumor-associated angiogenesis; enhancing tumor cell migration, invasion, and intravasation; and suppressing immunosurveillance. 60 Limited data are available on the regulation of macrophage function by PGE 2 . In a colon tumor implantation model, overexpression of 15-PGDH in tumor tissue is sufficient to redirect the differentiation of intratumoral CD11b cells from immunosuppressive M2-oriented TAMs to M1-oriented macrophages, 62 suggesting that PGE 2 can alter the differentiation of monocytes favoring the development of M2-type TAMs at the tumor sites. In a spontaneous murine model of gastric cancer, PGE 2 and bacterial infection promote tumor growth by cooperatively recruiting macrophages into tumors via up-regulation of CCL2 expression. 63 An in vitro study showed that treatment of LPS-activated macrophages with PGE 2 diminished LPSinduced TNF-> expression, suggesting that PGE 2 can downregulate cell-mediated immune responses (T H 1 response). 64 These studies suggest that PGE 2 may be able to recruit monocytes/macrophages to tumor sites and shift them to M2type macrophages (Fig. 3) . Moreover, PGE 2 is able to inhibit alveolar macrophage phagocytosis via multiple signaling pathways such as EP2-cAMP, 65 PTEN, 66 and IL-1RYassociated kinase-M. 67 However, there is no direct evidence demonstrating that PGE 2 regulates macrophage function during tumor initiation and progression.
B Cells
B cells not only function to produce antibodies against antigens but also as APCs for CD4 and CD8 T cells. At present, little is known about the role of B cells in human CRC and other solid tumors. In tumor implantation mouse models of CRC, B cellYdeficient mice exhibit spontaneous regression of tumor growth as compared with wild-type mice, 68 suggesting that B cells promote tumor growth.
Prostaglandin E 2 is able to inhibit B cell development in vivo. 69 In vitro studies further reveal that PGE 2 promotes B cell receptorYinduced apoptosis in immature B cells and inhibits B cell receptorYstimulated proliferation of mature B cells via EP4 70Y72 and B cell activation. 73 In addition, PGE 2 promotes the production of switched isotypes in B cells. For example, PGE 2 significantly induces immunoglobulin G1 (IgG1) production in resting B cells and uncommitted B cells expressing high levels of surface IgM. 74 Prostaglandin E 2 also induces activated B cell Ig isotype switching to IgE. 75 The PGE 2 induction of IgG1 and IgE supports the notion that PGE 2 acts predominantly to induce T H 2 responses (Fig. 3) . In the context of the colonic tumor microenvironment, however, the precise role of PGE 2 in B cells has not been investigated.
NK Cells
Although NK cells are functionally similar to cytotoxic T cells, NK cells are able to kill transformed or virus-infected cells but spare normal cells without prior sensitization. Suppressed NK cell activity has been found in human CRC and is an important prognostic factor for the development of distant metastases. 76, 77 Multiple studies have investigated the effects of PGE 2 on NK cells (Fig. 4) . In vivo studies showed that treatment of rats with PGE 2 inhibited NK cell activity and enhanced lung metastases 78 and reversed the effects of a NSAIDs on enhancing NK cell activity. 79 A recent report revealed that EP4 receptor mediated the effects of PGE 2 on suppression of NK cell function and promoted breast cancer metastasis in a syngeneic murine model of metastatic breast cancer. 80 Several in vitro studies have demonstrated that PGE 2 suppresses NK cell function. 81, 82 Prostaglandin E 2 not only directly inhibits NK cells to produce IFN-F, which is essential for NK cell functions, but also attenuates IL-12Yinduced or IL-18Yinduced IFN-F expression in NK cells via EP2 receptor signaling. 83, 84 Moreover, PGE 2 inhibits IL-15Yactivated human NK cell function through downregulation of common F-chain 85 and hepatic NK cell activities. 86 Prostaglandin E 2 reduces the cytotoxic activities of NK cells by inhibiting NK receptors including NKG2D, CD16, and natural cytotoxicity receptors (NCR: NKp30, NKp44, NKp46). 87 
Myeloid-Derived Suppressor Cells
Myeloid-derived suppressor cells are a heterogeneous population of immature myeloid cells that suppress T and NK cell functions. The levels of MDSC in the blood correlate with clinical cancer stage and metastatic tumor burden in mice and patients, including those diagnosed with colon cancer. 88, 89 It is widely accepted that MDSCs contribute to cancer immune evasion via suppressing functions of T and NK cells. 90 Emerging evidence demonstrates that MDSCs are also able to promote the development of FOXP3-positive Treg cells. 91 It has been reported that PGE 2 promoted tumor progression via inducing the differentiation of MDSCs from BM myeloid progenitor cells, whereas inhibition of PGE 2 signaling by deletion of EP2 or its antagonists blocked this differentiation in mice with implanted 4T1 mammary carcinoma 92 (Fig. 4) . Similarly, treatment of tumor-bearing mice with a COX-2 selective inhibitor prevented the local and systemic expansion of MDSCs in vivo. 93 In vitro studies showed that PGE 2 induced arginase I expression via EP4 in MDSCs. 94 Arginase I is involved in MDSC-mediated immune suppression by blocking effector T cell function. Prostaglandin E 2 also mediates the Fas ligationYinduced MDSC recruitment in 3LL Lewis lung carcinoma 95 and is required for CXCL4-induced MDSC chemotaxis via induction of CXCR4 expression on MDSCs. 96 However, the mechanism(s) by which PGE 2 regulates MDSC differentiation, expansion, and suppressive functions in cancers remains unclear.
T Cells

T Helper Cells
The progression of human CRC is associated with imbalance in T H 1/T H 2 responses with reduced production of cytokines from T H 1 cells and normal or even elevated levels of cytokines from T H 2 cells. 97Y99 Prostaglandin E 2 contributes to this imbalance by switching anti-tumor T H 1 responses to immunosuppressive T H 2 responses via down-regulation of T H 1 cytokines (TNF->, IFN-F, and IL-2) and up-regulation of T H 2 cytokines (IL-4, IL-10, and IL-6) in T helper cells. 100, 101 In addition, PGE 2 exacerbates inflammation and disease severity through elevating infiltration of IL-17Yproducing T helper (T H 17) cells to the colonic tissue in a murine model of inflammatory bowel disease. 55 In mammary glandYbearing mice, PGE 2 secreted from tumor induces IL-23, which results in T H 17 cell expansion in the tumor microenvironment. 102 In addition, PGE 2 can facilitate IL-23Yinduced T H 17 expansion from peripheral blood mononuclear cells and naive T cells in vitro. 103, 104 Prostaglandin E 2 also directly promotes differentiation of memory CD4 + T cells to T H 17 cells by induction of IL-17 expression and reduction of IFN-F expression. 105 Prostaglandin E 2 induces T H 1 cell differentiation and T H 17 cell expansion in vitro, and treatment with an EP4 antagonist reduces accumulation of both T H 1 and T H 17 cells in regional lymph nodes and suppresses the disease progression in an animal model of chronic inflammation. 106 However, relatively little is known about the impact of PGE 2 on the imbalance of T H 1/T H 2 response and T H 17 cells in tumor microenvironment.
CD8 + T Cells
The massive infiltration of CD8 + T cells at the site of tumors is significantly associated with a better survival of CRC patients. 107 Although much less is known about directly suppressive effects of PGE 2 on CD8 + T cells, a few reports indicated that PGE 2 can directly inhibit CD8 + T cell proliferation 108 and the cytotoxic activity of CD8 + T cells via up-regulation of CD94 and the NKG2A complex in vitro. 109 Prostaglandin E 2 also attenuates T-cell receptor (TCR)-induced IFN-F release from CD8 + T cells. 110 Reduction of IFN-F production favors type 2 responses in general. In addition to the direct effects of PGE 2 on CD8 + T cells, PGE 2 produced by cancer cells and their surrounding stromal cells can also indirectly abolish the antitumor effects of cytotoxic T cells in vivo and in vitro through down-regulation of both direct antigen presentation by tumor cells and cross-presentation by APCs such as DCs. 111 
Regulatory T Cells
Regulatory T cells are essential for suppressing immune responses and maintaining self-tolerance by regulating the activity of other immune cells. The frequency and suppressor function of Treg cells are elevated in the peripheral blood and at the tumor sites of cancer patients including CRC. 112, 113 There is a positive correlation between PGE 2 levels and the numbers of FOXP3 + Treg cells in peripheral blood, tumor tissues, and draining lymph nodes of CRC patients. 114 In the polyps of Apc$ 468 mice, Treg cells shift from a protective anti-inflammatory (CD4 + CD45RB low CD25 high ) to a cancer-promoting proinflammatory phenotype (CD4 + CD25 + FOXP3 + ). 115 In a mouse model, deletion of mPges-1 gene suppresses AOM-induced colon carcinogenesis accompanied with reduced frequency of CD4 + FOXP3 + Treg cells in the draining mesenteric lymph nodes and serum PGE 2 levels, 116 indicating that PGE 2 may enhance tumor growth via expansion of Treg cells. Moreover, PGE 2 can directly enhance the differentiation of naive CD4 + T cells into FOXP3-positive Treg cells in vitro and induce FOXP3 expression and Treg activities in lung cancer in vivo. 117, 118 Prostaglandin E 2 has also been reported to indirectly attract FOXP3 + Treg cells via induction of CCL22 in mature DCs 119 (Fig. 3) . Interestingly, CD4 + CD25 + FOXP3 + Treg cells produce PGE 2 and suppress effector T cell responses in a PGE 2 -dependent manner. 120 In addition, treatment with an EP4 antagonist resulted in a decreased number of Treg cells in lymph nodes and the skin after UV irradiation, 121 suggesting that EP4 mediates the effect of PGE 2 on Treg expansion. An in vitro study indicated that PGE 2 secreted from breast cancer cells induced Treg cell migration. 122 Collectively, PGE 2 -enhanced Treg expansion, migration, and activities provide another mechanism for contribution of PGE 2 to promotion of an immunosuppressive microenvironment (Fig. 4 ).
Mast Cells
Although mast cells (MCs) are key effector cells in allergic diseases, it has become apparent that they also contribute to other diseases, including cancer. Recent studies revealed that lower numbers of MCs are associated with hypovascularity and better survival in CRC patients. 123 In contrast, higher MC infiltration is associated with poor clinical outcome with increased vascularity, tumor growth, and invasion in many of human cancers including CRC. 124, 125 In Apc$ 468 mice, MCs have been demonstrated to be an essential component for polyp growth. 126 These findings suggest that the infiltration of MCs into tumor contributes the tumor growth.
Prostaglandin E 2 functions as a chemotactic factor for immature and mature BM-derived MCs (BM-MCs) in vitro and in vivo. 127 The PI3K-mTOR signaling pathway mediates the effects of PGE 2 on attracting BM-MCs. 128 Moreover, PGE 2 has been shown to enhance MC induction from murine spleen mononuclear cells and BM-MCs as well as human umbilical cord blood mononuclear cells. 129Y131 In addition, PGE 2 promotes release of proinflammatory cytokines and chemokines as well as proangiogenic factors such as IL-6, CCL2, and vascular endothelial growth factor A from BM-MCs, human umbilical cord blood mononuclear cellYderived MCs, and spleen-derived MCs. 131Y133 These results indicate that PGE 2 promotes colon tumor growth via enhancing recruiting MCs, MC maturation, stimulating MCs to produce proinflammatory cytokines and chemokines as well as proangiogenic factors (Fig. 4 ).
CONCLUSIONS
Prostaglandin E 2 promotes cancer progression via several mechanisms. Prostaglandin E 2 can directly bind to its cell surface receptors on tumor epithelial cells to regulate cell proliferation, apoptosis, migration, and invasion as well as to induce tumor epithelial cells to secrete growth factors, proinflammatory mediators, and angiogenic factors that stimulate angiogenesis and promote local inflammation. In addition to the direct effects of PGE 2 on tumor cells, PGE 2 also serves as an immunomodulator that shifts the tumor microenvironment from anti-tumor to immunosuppressive responses, resulting in escape of tumor cells from effective immunosurveillance.
Most cancer immunotherapies have had poor clinical efficiency. The observations that use of selective COX-2 inhibitors enhances the efficacy of certain cancer vaccines 134Y136 support a hypothesis that a major barrier to successful immunotherapies against cancer is the immune modulators secreted by cancer cells and their surrounding stromal cells, such as PGE 2 . Therefore, understanding the diverse functions of PGE 2 in the tumor microenvironment is crucial for the development of novel combinational therapies aimed at targeting PGE 2 production and signaling along with immune intervention for prevention and amelioration of CRC with decreased cardiovascular adverse effects associated with selective COX-2 inhibitors and enhanced efficacy of immunotherapies.
